Therapie des epithelialen Ovarialkarzinomrezidivs

Medicine and Dentistry

• Recurrent Disease 100%
• Krukenberg Tumor 100%
• Olaparib 66%
• Doxorubicin 66%
• Rucaparib 66%
• Niraparib 66%
• Ovarian Cancer 33%
• Tumor Biology 33%
• Angiogenesis Inhibitor 33%
• Clinical Study 33%
• Combination Therapy 33%
• Therapeutic Use 33%
• Bevacizumab 33%
• Gemcitabine 33%
• Allergic Response 33%
• Predictive Factor 33%
• Electrocorticography 33%
• Topotecan 33%
• Female Genital Tract Tumor 33%
• Carboplatin 33%
• Paclitaxel 33%
• Patient History of Chemotherapy 33%
• Trabectedin 33%
• BRCA Mutation 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Ovary Carcinoma 100%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor 100%
• Recurrent Disease 100%
• Doxorubicin 66%
• Rucaparib 66%
• Niraparib 66%
• Ovary Cancer 33%
• Paclitaxel 33%
• Clinical Study 33%
• Carboplatin 33%
• Allergic Reaction 33%
• Therapeutic Use 33%
• Patient History of Chemotherapy 33%
• Neoplasm 33%
• Combination Therapy 33%
• Topotecan 33%
• Gemcitabine 33%
• Trabectedin 33%
• Female Genital Tract Tumor 33%